Latest News

China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA

The designation, for the PD-1 inhibitor toripalimab in nasopharyngeal carcinoma, makes the Shanghai-based company the latest of several Chinese biotech firms to make headway in the U.S. market.

Source link

Related posts

Peer Problems and Low Self-esteem Mediate the Suspicious and Non-suspicious Schizotypy-Reactive Aggression Relationship in Children and Adolescents


Antibiotics Pollute Rivers Worldwide, Study Finds


Study shows possibility to predict who would benefit from exercise and behavioral therapy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World